Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type: ]5 p6 P h( ], W- G" ^
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 3 @7 S# T* K4 M% A) w0 [
+ Author Affiliations
8 ]6 R/ l F8 K) m- A4 n$ p
: z+ k+ k( y) H" K: I/ _3 u1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
" w1 H% e1 p3 M: f+ K2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
1 g# d' V# P; o, p/ l6 X3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ m9 Q. t2 r* h- `: Q7 M4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan # r. t& N; P$ d; Q- \, d1 C
5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 7 _( b# ~. {1 n7 j3 C U
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 5 p7 ~; i" Q/ ?0 W4 e4 g
7Kinki University School of Medicine, Osaka 589-8511, Japan
. H1 i( X, H( |+ ?# a8Izumi Municipal Hospital, Osaka 594-0071, Japan ! K; K3 n6 V/ H. }
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
/ H: u& { y1 |6 r& i9 RCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; k9 |; F5 d( T0 X
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. / x. u" T( T! p7 }& m- P
- o* V0 p+ P V2 q |